HC Wainwright & Co. Maintains Buy on Avalo Therapeutics, Raises Price Target to $40

Benzinga Newsdesk www.benzinga.com Positive 71.8%

Neg 0% Neu 0% Pos 71.8%

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and raises the price target from $25 to $40.